MedTrace Logo

A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

NCT05141240 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4650

Last updated 2021-12-16

No results posted yet for this study

Summary

This is a retrospective cohort study to assess the real-world analysis of concomitant medication use among metastatic breast cancer patients treated with CDK4/6 inhibitors utilizing the US Optum research administrative claims database.

Conditions

Interventions

DRUG

Ribiciclib

Participants who initiated CDK4/6i therapy

DRUG

Palbociclib

Participants who initiated CDK4/6i therapy

DRUG

Abemaciclib

Participants who initiated CDK4/6i therapy

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-15
Primary Completion
2020-06-15
Completion
2020-06-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05141240 on ClinicalTrials.gov